Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte and platelets score

Heba Taha; Dalia Elsayed; Reham Salem; Doaa Mandour; Mohammed Bayomy; Hayam Rashed; Mostafa Kamel; Mohamed Elderey; Ola Elfarargy

doi:10.5114/wo.2022.120592

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2022
vol. 26

Send email

Copy url:

abstract:

Original paper

Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte and platelets score

Heba F. Taha

¹

,

Dalia Hamouda Elsayed

¹

,

Reham Salem

²

,

Doaa Mandour

²

,

Mohammed Bayomy

²

,

Hayam Rashed

³

,

Mostafa Kamel

⁴

,

Mohamed Elderey

⁴

,

Ola M. Elfarargy

¹

Medical Oncology Department, Zagazig University, Zagazig, Egypt
Clinical Oncology and nuclear medicine department, Zagazig University, Zagazig, Egypt
Pathology Department, Zagazig University, Zagazig, Egypt
Urology Department, Zagazig University, Zagazig, Egypt

Contemp Oncol (Pozn) 2022; 26 (3): 196–203

DOI: https://doi.org/10.5114/wo.2022.120592

Online publish date: 2022/10/24

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Taha HF, Elsayed DH, Salem R, et al. Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte and platelets score. Contemporary Oncology/Współczesna Onkologia. 2022;26(3):196-203. doi:10.5114/wo.2022.120592.

APA

Taha, H. F., Elsayed, D. H., Salem, R., Mandour, D., Bayomy, M.,  & Rashed, H. et al. (2022). Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte and platelets score. Contemporary Oncology/Współczesna Onkologia, 26(3), 196-203. https://doi.org/10.5114/wo.2022.120592

Chicago

Taha, Heba F, Dalia H Elsayed, Reham Salem, Doaa Mandour, Mohammed Bayomy, Hayam Rashed,  and Mostafa Kamel et al. 2022. "Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte and platelets score". Contemporary Oncology/Współczesna Onkologia 26 (3): 196-203. doi:10.5114/wo.2022.120592.

Harvard

Taha, H., Elsayed, D., Salem, R., Mandour, D., Bayomy, M., Rashed, H., Kamel, M., Elderey, M.,  and Elfarargy, O. (2022). Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte and platelets score. Contemporary Oncology/Współczesna Onkologia, 26(3), pp.196-203. https://doi.org/10.5114/wo.2022.120592

MLA

Taha, Heba et al. "Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte and platelets score." Contemporary Oncology/Współczesna Onkologia, vol. 26, no. 3, 2022, pp. 196-203. doi:10.5114/wo.2022.120592.

Vancouver

Taha H, Elsayed D, Salem R, Mandour D, Bayomy M, Rashed H et al. Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte and platelets score. Contemporary Oncology/Współczesna Onkologia. 2022;26(3):196-203. doi:10.5114/wo.2022.120592.

PlumX metrics:

Introduction
We aimed to evaluate the outcome of treatment with docetaxel plus androgen deprivation therapy (ADT) in newly diagnosed patients with metastatic high tumor burden hormone-sensitive prostate cancer (mHSPC) and correlated the outcome with hemoglobin, albumin, lymphocyte and platelets (HALP) score.

Material and methods
Six cycles of docetaxel plus ADT were given to 50 patients with high burden mHSPC. Baseline HALP score was calculated and disease outcome was tabulated; moreover, the prognostic impact of the HALP score in response to treatment and survival was calculated.

Results
We found a significant association between high HALP score and response to treatment where a higher rate of complete response occurred in patients with a high HALP score than in patients with a low HALP score (53.8% vs. 5.4% respectively, p-value = 0.001). Patients with ≥ 12-month-duration castration-resistant prostate cancer (CRPC) had a significantly higher HALP score compared to patients with a lower HALP score (84.6% vs. 35.1% respectively, p-value = 0.002); 18-month-duration CRPC-free survival was significantly greater in patients with higher HALP score than patients with a lower HALP score (23.1% and 5.4% respectively, p-value < 0.001). Patients with a high HALP score had insignificantly higher mean overall survival than patients with a low HALP score (mean: 22.91 and 20.66 months respectively, p-value = 0.230).

Conclusions
Our results confirmed the benefits of treatment with docetaxel plus ADT in high-burden mHSPC with accepted tolerance. HALP score was found to be an independent predictive factor for benefit from therapy; we can apply it as an easy way to stratify patients for appropriate selection of treatment for better tolerance and outcome.

keywords:

Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte and platelets score

Heba F. Taha 1 , Dalia Hamouda Elsayed 1 , Reham Salem 2 , Doaa Mandour 2 , Mohammed Bayomy 2 , Hayam Rashed 3 , Mostafa Kamel 4 , Mohamed Elderey 4 , Ola M. Elfarargy 1

metastatic prostatic cancer, high burden, hormone-sensitive, docetaxel, HALP score

Heba F. Taha

¹

,

Dalia Hamouda Elsayed

¹

,

Reham Salem

²

,

Doaa Mandour

²

,

Mohammed Bayomy

²

,

Hayam Rashed

³

,

Mostafa Kamel

⁴

,

Mohamed Elderey

⁴

,

Ola M. Elfarargy

¹